Ongoing Research Funded by DHF
Does an Inflammatory Bowel Disease Flare Impact the Results of the Prostate Specific Anitigen (PSA) Test Used to Screen for Prostate Cancer?
Principal Investigator: Shilajit D. Kundu, MD
One million-plus Americans have IBD, accounting for more than two million ambulatory and emergency room visits annually. This health care utilization can lead to annual medical expenditures ranging from $5,000 to $8,000 per patient. Reducing unnecessary medical costs in this patient group is paramount. Take for example, PSA tests. While PSA screening can reduce prostate cancer deaths, false-positive elevations commonly occur, especially for patients with IBD. The Kundu research group recently found that men 65 and older with IBD, who underwent prostate cancer screening at Northwestern Memorial Hospital, had higher PSA values than non-IBD controls. In addition, men with IBD had a significantly higher risk of prostate cancer. However, whether the elevation in PSA is due to IBD-related inflammation versus a true reflection of an increased risk of prostate cancer remains unclear. Study findings may optimize how men with IBD are screened for prostate cancer by better assessing their risk while at the same time reducing needless medical expenses.
To receive Digestive Health Foundation updates on research, free education events, and the 2019 Gala, please fill in your information and click 'Submit.'